Fierce Pharma

AUGUST 27, 2024

An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview. . | In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services.

Biopharma 304

Biopharma FDA Pharma Healthcare 304

Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma 246

Biopharma Patients 246

Fierce Pharma

MAY 16, 2024

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.

Biopharma 299

Biopharma Pharma 299

Fierce Pharma

AUGUST 21, 2024

A survey of 800 biopharma executives shows that sustainability is an increasingly important priority but that companies are struggling to achieve it.

Biopharma 280

Biopharma Pharma 280

Fierce Pharma

MAY 29, 2024

Already weathering the complex biopharma landscape in the U.S. | A tsunami of regulations will require biopharma to look to the high ground of knowledgeable partners

Biopharma 130

Biopharma 130

Fierce Pharma

SEPTEMBER 7, 2023

Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.

Biopharma 334

Biopharma Pharma 334

Fierce Pharma

JUNE 14, 2023

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma 289

Biopharma 289

Fierce Pharma

MARCH 21, 2023

Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14

Biopharma 258

Biopharma Manufacturing 258

Fierce Pharma

JANUARY 16, 2024

A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. 2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. |

Biopharma 234

Biopharma 234

Fierce Pharma

MAY 16, 2023

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma 293

Biopharma 293

Fierce Pharma

FEBRUARY 29, 2024

Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.

Biopharma 277

Biopharma Pharma 277

Fierce Pharma

MAY 22, 2023

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04

Biopharma 287

Biopharma Sales 287

Fierce Pharma

SEPTEMBER 14, 2023

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma 231

Biopharma Pharmaceutical 231

Fierce Pharma

JUNE 26, 2023

But there was no evidence of the slide in biopharma where pay increases were plentiful. There was a decline in CEO compensation overall in 2022.

Biopharma 176

Biopharma 176

European Pharmaceutical Review

JUNE 7, 2023

The global biopharma industry’s resilience has decreased since 2021, a report by Cytiva has found. Using feedback from 1250 pharma and biopharma executives in 22 countries, the research sought to find out how has the biopharma industry has evolved over the past two years and what areas the industry should seek to improve.

Biopharma 97

Biopharma Government Manufacturing Pharma 97

Fierce Pharma

JANUARY 8, 2024

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

Prospecting 258

Prospecting Biopharma Pharma Healthcare 258

Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S.

Biopharma 323

Biopharma Pharma 323

Fierce Pharma

NOVEMBER 18, 2024

may not rock the boat as much as feared for the biopharma industry. Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr.

Biopharma 291

Biopharma FDA Marketing 291

Fierce Pharma

OCTOBER 3, 2024

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients 130

Patients Biopharma Management Pharma 130

Fierce Pharma

DECEMBER 20, 2022

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.

Biopharma 259

Biopharma 259

Fierce Pharma

MAY 9, 2023

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18

Biopharma 236

Biopharma 236

Fierce Pharma

MAY 25, 2023

The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21

Biopharma 209

Biopharma 209

Fierce Pharma

DECEMBER 21, 2022

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.

Biopharma 212

Biopharma 212

Fierce Pharma

AUGUST 15, 2023

As the coronavirus surged and subsided, several biopharma companies experienced exaggerated revenue spikes and troughs. Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far.

Biopharma 246

Biopharma Sales Pharma 246

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

Biopharma 215

Biopharma 215

Fierce Pharma

SEPTEMBER 25, 2023

A who’s who of biopharma companies have backed a push to rai | A who’s who of biopharma companies have backed a push to raise awareness about lung cancer among Hispanic and Latino Americans, funding a project that has enlisted a Mission: Impossible star to educate the community about risk factors, early warning signs and screening.

Biopharma 207

Biopharma Education Pharma 207

Fierce Pharma

JUNE 6, 2024

More Chinese biopharma players are coming under scrutiny from U.S. . | AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual meeting, a cancer antibody from Akeso and Summit Therapeutics stole the show.

Biopharma 210

Biopharma Pharma Patients 210

PharmExec

NOVEMBER 5, 2024

At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be implemented to support successful healthcare transformation.

Pharma 52

Pharma Biopharma Healthcare Healthcare 52

Fierce Pharma

NOVEMBER 27, 2023

It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly’s fortunes have turned quickly. | Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively.

Biopharma 292

Biopharma Pharma 292

MedCity News

MAY 13, 2024

In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management. The post Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business appeared first on MedCity News.

Prescription 116

Prescription Medicine Pharma Biopharma 116

Fierce Pharma

MAY 9, 2023

We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56

Biopharma 157

Biopharma 157

European Pharmaceutical Review

JULY 7, 2023

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.

Competition 104

Competition Biopharma Government Manufacturing 104

MedCity News

OCTOBER 3, 2023

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

Biopharma 118

Biopharma Pharma 118

Fierce Pharma

MAY 18, 2023

The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13

Biopharma 144

Biopharma 144

Fierce Pharma

SEPTEMBER 11, 2023

The adoption of technology and data by biopharma is driving a digital transformation in manufacturing, accelerating the process of bringing molecules from benchside to bedside. My name is Gaurav Marya. I am the Strategic Business Unit Head and Global Head of Mergers and Acquisitions for Life Sciences at Cognizant. |

Manufacturing 196

Manufacturing Biopharma Pharma 196

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. |

Biopharma 326

Biopharma FDA 326

European Pharmaceutical Review

MARCH 31, 2023

GlobalData Pharma Intelligence Center Deals Database found: SVB Financial Group and its subsidiaries were involved in more than $1.4 A Danish pharma company developing peptide-based medicines, expects to recover its $23.4 The post Biopharma could reap benefits from SVB UK acquisition appeared first on European Pharmaceutical Review.

Biopharma 98

Biopharma Pharma Networking Marketing 98